Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Next Previous
Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary)
  • Indications Chronic lymphocytic leukaemia; Skin cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms C-POST
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 31 May 2025 Primary endpoint(DFS defined as time from randomization to the first documented disease recurrence (local, regional and/or distant); or death due to any cause.) has been met.
  • 31 May 2025 According to a Regeneron Pharmaceuticals media release, data from this trial was shared during an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine (NEJM).
  • 31 May 2025 Results presented in the Regeneron Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top